What Are GHRPs?
Growth Hormone Releasing Peptides (GHRPs) are a class of synthetic peptides that stimulate the secretion of growth hormone (GH) from the anterior pituitary gland. Unlike GHRH (growth hormone-releasing hormone) analogs that act through the GHRH receptor, GHRPs act primarily through the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor.
The GHRP class was discovered in the 1980s and has since become one of the most important tools in growth hormone research. GHRPs work by mimicking the action of ghrelin, the endogenous GHS-R1a ligand, but with improved selectivity and pharmacokinetic profiles.
The GHRP Family
GHRP-6
The first clinically studied GHRP. GHRP-6 is a hexapeptide (6 amino acids) that potently stimulates GH release but also significantly increases appetite (via hypothalamic ghrelin signaling), elevates cortisol, and raises prolactin levels. These off-target effects limit its utility in research requiring isolated GH stimulation.
GHRP-2
An improved hexapeptide with stronger GH-releasing activity than GHRP-6 and moderate cortisol/prolactin elevation. GHRP-2 represents an intermediate selectivity profile between GHRP-6 and ipamorelin.
Hexarelin
One of the most potent GHRPs in terms of raw GH release. However, it produces the most significant cortisol and prolactin increases of the GHRP family, and research suggests rapid tachyphylaxis (decreased response with repeated use).
Ipamorelin
The most selective GHRP, producing robust GH release with minimal effects on cortisol, prolactin, and ACTH. Ipamorelin’s clean pharmacological profile has made it the preferred GHRP for modern research. See our complete Ipamorelin Research Guide for details.
Mechanism of Action
All GHRPs activate the GHS-R1a receptor on pituitary somatotrophs, triggering GH release through a signaling cascade involving:
- GHS-R1a activation ? Gq protein coupling
- Phospholipase C (PLC) activation
- IP3 production ? intracellular calcium release
- Protein kinase C (PKC) activation
- GH granule exocytosis
This calcium/PKC pathway is distinct from and complementary to the cAMP/PKA pathway used by GHRH analogs, which is why combining a GHRP with a GHRH analog produces synergistic GH release.
GHRPs vs GHRH Analogs
| Feature | GHRPs | GHRH Analogs |
|---|---|---|
| Receptor | GHS-R1a (ghrelin receptor) | GHRH receptor |
| Signaling | Ca²?/PKC | cAMP/PKA |
| GH Release Pattern | Acute pulse | Amplifies existing pulse |
| Examples | Ipamorelin, GHRP-6, GHRP-2 | CJC-1295, Tesamorelin |
| Synergy Together? | Yes — complementary pathways produce 2-3x GH release | |
Research Applications
- Growth hormone secretion dynamics and pulsatility
- GHS-R1a receptor pharmacology
- Body composition and metabolic research
- Bone density and skeletal research
- GI motility studies (ghrelin receptor is expressed in the gut)
- Appetite and feeding behavior research
Conclusion
GHRPs are indispensable tools for growth hormone research, offering researchers control over GH secretion through the ghrelin receptor pathway. The evolution from GHRP-6 to ipamorelin demonstrates the progress toward increasingly selective compounds, and the synergistic combination of GHRPs with GHRH analogs remains the gold standard for GH axis stimulation research.
All products are sold strictly for research purposes only. Not for human consumption.